Ulcerative Colitis Clinical Trials in New Albany, Indiana

4 studies are recruiting for ulcerative colitis in New Albany, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

    This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 286 weeks including: * 40…

    Stage
    Phase 3
    Ages
    16 to 80
    Site
    Gastroenterology Health Partners, PLLC - New Albany - Site Number: 8400100, New Albany, Indiana
    Locations
    55 in total
    Run by
    Sanofi

    See if you can join NCT07185009 on ClinicalTrials.gov

  2. LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

    The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 wee…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    Gastroenterology Health Partners, New Albany, Indiana
    Locations
    147 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07186101 on ClinicalTrials.gov

  3. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

    The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation …

    Stage
    Phase 3
    Ages
    18 to 70
    Site
    Gastroenterology Health Partners, New Albany, Indiana
    Locations
    187 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06937086 on ClinicalTrials.gov

  4. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

    This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks wi…

    Stage
    Phase 3
    Ages
    16 to 80
    Site
    Gastroenterology Health Partners, PLLC - Site Number: 8400100, New Albany, Indiana
    Locations
    219 in total
    Run by
    Sanofi

    See if you can join NCT07184996 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.